par Tolaney, Sara S.M.;Winer, Eric E.P.;Nechushtan, Hovav;Ron, Ilan Gil;Schöffski, Patrick;Awada, Ahmad ;Yasenchak, Christopher C.A.;Laird, Alexander Douglas;O’Keeffe, Bridget;Shapiro, Geoffrey G.I.
Référence Breast cancer research and treatment, 160, 2, page (305-312)
Publication Publié, 2016-11
Référence Breast cancer research and treatment, 160, 2, page (305-312)
Publication Publié, 2016-11
Article révisé par les pairs
Titre: |
|
Auteur: | Tolaney, Sara S.M.; Winer, Eric E.P.; Nechushtan, Hovav; Ron, Ilan Gil; Schöffski, Patrick; Awada, Ahmad; Yasenchak, Christopher C.A.; Laird, Alexander Douglas; O’Keeffe, Bridget; Shapiro, Geoffrey G.I. |
Informations sur la publication: | Breast cancer research and treatment, 160, 2, page (305-312) |
Statut de publication: | Publié, 2016-11 |
Sujet CREF: | Cancérologie |
Mots-clés: | Cabozantinib |
Metastatic breast cancer | |
Overall survival | |
Progression-free survival | |
Tumor response | |
Vascular endothelial growth factor receptor | |
Note générale: | SCOPUS: ar.j |
Langue: | Anglais |
Identificateurs: | urn:issn:0167-6806 |
info:doi/10.1007/s10549-016-4001-y | |
info:scp/84990842006 |